Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.
A phase 1/2 trial of ZG006 in neuroendocrine tumours, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.
Overview
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma. is a phase 1/2 interventional study registered as NCT06440057 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 78 participants planned, started 2024-08-29 and due to reach its primary completion in 2026-05. Interventions recorded: ZG006.
Similar pages
not linked directly; found by shared links- TrialStudy of ZGGS34 in Participants With Advanced Solid Tumors
Shares ZG006, Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
- TrialStudy of ZGGS18 in Patients With Advanced Solid Tumors
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
- TrialStudy of ZG005 in Patients With Advanced Solid Tumors
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
- TrialStudy of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
- TrialStudy of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
- TrialStudy of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
- TrialStudy Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
Shares ZG006, Suzhou Zelgen Biopharmaceuticals.
- TrialStudy of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Shares ZG006, Suzhou Zelgen Biopharmaceuticals.